Swedish Orphan Biovitrum made waves yesterday by getting its rare disease asset emapalumab into the Ash late-breakers – and bagging approval soon afterwards.
Discontinuations and an unusual revelation about Tecentriq’s breast cancer data dominated the R&D part of the company’s third-quarter results call.
Celgene’s surprise termination of a clinical trial makes for a day of soul-searching among other followers of the anti-CD47 approach.
Next-generation projects, including gene therapies, could soon be shaking up the haemophilia market.
Experts expect Roche's Hemlibra to dominate the inhibitor patient population, but to be a big deal it will need to impress in non-inhibitor patients, too.